The Innovative Targets Portfolio: Basic Life Sciences Research to Novel Therapies, through a Portfolio of Small Molecule Translational Projects (CiC 2017)

Lead Research Organisation: University of Dundee

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description Defining the role of PKN2 in cancer-associated fibroblasts
Amount £99,773 (GBP)
Funding ID SBF001\1004 
Organisation Academy of Medical Sciences (AMS) 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2016 
End 08/2018
 
Description Development of a novel treatment for pancreatic cancer by targeting normal cells within the pancreas, which help cancer to develop
Amount £24,000 (GBP)
Funding ID M483 
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2015 
End 09/2018
 
Description Discovery of specific inhibitors of the cellular response to interferon
Amount £50,000 (GBP)
Organisation Newcastle University 
Sector Academic/University
Country United Kingdom
Start 07/2018 
End 12/2018
 
Description tau seeding collaboration with Takeda 
Organisation Medical Research Council (MRC)
Department MRC Laboratory of Molecular Biology (LMB)
Country United Kingdom 
Sector Academic/University 
PI Contribution DDU screened an assay deriveing 6 series of novel chemotypes. The chemotypes were expanded using medicinal chamistry to show cell based activity in parallel with good CNS penetration and DMPK properties. The DDU will move these series forward to idnetify targets and deliver compounds ready for pre-candidate selection.
Collaborator Contribution Partners provided a screening assay for interrogating tau seeding. Partners will support profiling of molecules in secondary assays and, if appropriate, in animal models of disease.
Impact None as yet
Start Year 2019
 
Description tau seeding collaboration with Takeda 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution DDU screened an assay deriveing 6 series of novel chemotypes. The chemotypes were expanded using medicinal chamistry to show cell based activity in parallel with good CNS penetration and DMPK properties. The DDU will move these series forward to idnetify targets and deliver compounds ready for pre-candidate selection.
Collaborator Contribution Partners provided a screening assay for interrogating tau seeding. Partners will support profiling of molecules in secondary assays and, if appropriate, in animal models of disease.
Impact None as yet
Start Year 2019